If you are attending this year's C5 Life Sciences IP Summit (programme
here) in Berlin on 22 to 23 October 2015, it has a session on SPCs that looks like this:
4:15 to 5:30 A Case-Law Review of the Jurisprudence on Supplementary Protection Certificates in Europe
Matthew Royle
Partner
Taylor Wessing (United Kingdom)
- Lessons learnt from C-493/12 (Lilly-HGS), C-631/13 (Forsgren), E-16/14 (Pharmaq-Intervet)
- An overview of the pending referrals concerning SPCs before the CJEU
- Understanding under which circumstances you can obtain an SPC in the context of antibody claims
- Obtaining an SPC on combinations of active ingredients for new uses
- Neurim’s, Medeva’s, Georgetown’s, AstraZeneca’s, Merck’s aftermath: an overview of the CJEU’s interpretation on development of a new indication from an old substance
IPKat blog readers can get a 15% reduction on the registration fee: details can be found
here.
